Marius Stephan Horger

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background This study evaluated efficacy and safety of pemetrexed in patients with refractory soft tissue sarcoma. Methods Patients received pemetrexed intravenously at a dose of 500 mg/m² every 21 days until progression or unacceptable toxicity. The primary endpoint was objective tumor response. Results Fourty-eight of 53 screened patients were included(More)
  • 1